These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1341931)

  • 1. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?
    Drummond M
    Health Econ; 1992 Jul; 1(2):85-92. PubMed ID: 1341931
    [No Abstract]   [Full Text] [Related]  

  • 2. Implications of the Australian guidelines for the United States.
    Freund DA; Evans D; Henry D; Dittus R
    Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641
    [No Abstract]   [Full Text] [Related]  

  • 3. Basing prescription drug payment on economic analysis: the case of Australia.
    Drummond MF
    Health Aff (Millwood); 1992; 11(4):191-6. PubMed ID: 1483639
    [No Abstract]   [Full Text] [Related]  

  • 4. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.
    Bae G; Bae EY; Bae S
    Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
    Viney R
    Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
    [No Abstract]   [Full Text] [Related]  

  • 6. A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.
    Lingaratnam SM; Kirsa SW; Mellor JD; Jackson J; Crellin W; Fitzsimons M; Zalcberg JR
    Aust Health Rev; 2011 May; 35(2):204-10. PubMed ID: 21612735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug reimbursement--an international headache].
    Bryn E; Hågå A; Madsen S
    Tidsskr Nor Laegeforen; 2002 Nov; 122(27):2592. PubMed ID: 12523183
    [No Abstract]   [Full Text] [Related]  

  • 8. Issues in mandatory economic assessment of pharmaceuticals.
    Bloom BS
    Health Aff (Millwood); 1992; 11(4):197-201. PubMed ID: 1483640
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of economic evaluation in the pricing and reimbursement of medicines.
    Drummond M; Jönsson B; Rutten F
    Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness/efficacy difference too often ignored.
    Silverman E
    Manag Care; 2013 Jan; 22(1):36. PubMed ID: 23373138
    [No Abstract]   [Full Text] [Related]  

  • 11. Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?
    Faunce TA
    Med J Aust; 2007 Aug; 187(4):240-2. PubMed ID: 17564579
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
    Dalton A
    Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
    Wonder M; Dunlop S
    Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of reimbursement applications for new drugs].
    Aaserud M; Trommald M; Oxman AD; Innvaer S
    Tidsskr Nor Laegeforen; 2002 Nov; 122(27):2619-23. PubMed ID: 12523192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 19. Antipodean assessment. Activities, actions, and achievements.
    Mitchell AS
    Int J Technol Assess Health Care; 2002; 18(2):203-12. PubMed ID: 12053421
    [No Abstract]   [Full Text] [Related]  

  • 20. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
    Drummond M
    J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.